In his new role, Dr. Zheng will be tasked with developing and leading a comprehensive translational and basic science research program for melanoma by working closely with the organization’s surgical and medical oncology leadership team, according to an April 16 news release from Cedars-Sinai.
Dr. Zheng’s research focuses on how the metabolism of melanoma cancer cells and the tumor microenvironment influence resistance mechanisms to existing immunotherapies, such as checkpoint inhibitors, which fight cancer with a patient’s immune system.
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
